Collegium Pharmaceutical Inc
NASDAQ:COLL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Collegium Pharmaceutical Inc
Depreciation & Amortization
Collegium Pharmaceutical Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Collegium Pharmaceutical Inc
NASDAQ:COLL
|
Depreciation & Amortization
$226.1m
|
CAGR 3-Years
19%
|
CAGR 5-Years
30%
|
CAGR 10-Years
102%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Depreciation & Amortization
$7.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Depreciation & Amortization
$4B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
27%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Depreciation & Amortization
$6.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Depreciation & Amortization
$5.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Depreciation & Amortization
$2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
Collegium Pharmaceutical Inc
Glance View
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
See Also
What is Collegium Pharmaceutical Inc's Depreciation & Amortization?
Depreciation & Amortization
226.1m
USD
Based on the financial report for Dec 31, 2025, Collegium Pharmaceutical Inc's Depreciation & Amortization amounts to 226.1m USD.
What is Collegium Pharmaceutical Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
102%
Over the last year, the Depreciation & Amortization growth was 34%. The average annual Depreciation & Amortization growth rates for Collegium Pharmaceutical Inc have been 19% over the past three years , 30% over the past five years , and 102% over the past ten years .
